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Abstract
Treatment switching in a randomised controlled trial occurs when participants change from their 
randomised treatment to the other trial treatment during the study. Failure to account for treatment 
switching in the analysis (i.e. by performing a standard intention-to-treat analysis) can lead to 
biased estimates of treatment efficacy. The rank preserving structural failure time model 
(RPSFTM) is a method used to adjust for treatment switching in trials with survival outcomes. The 
RPSFTM is due to Robins and Tsiatis (1991) and has been developed by White et al. (1997, 
1999).
The method is randomisation based and uses only the randomised treatment group, observed event 
times, and treatment history in order to estimate a causal treatment effect. The treatment effect, ψ, 
is estimated by balancing counter-factual event times (that would be observed if no treatment were 
received) between treatment groups. G-estimation is used to find the value of ψ such that a test 
statistic Z(ψ) = 0. This is usually the test statistic used in the intention-to-treat analysis, for 
example, the log rank test statistic.
We present an R package that implements the method of rpsftm.
Introduction
In a two-arm randomised controlled trial, participants are randomly allocated to receive one 
of two treatments or interventions. Ideally, all participants would fully receive their allocated 
treatment and no other treatment. However, in a recent review, 98 of 100 trials published in 
four high quality general medical journals reported some form of departure from randomised 
treatment (Dodd et al., 2012). When treatment is ‘all-or-nothing’ (for example, a surgical 
procedure), possible departures include not receiving the allocated treatment, receiving the 
other trial treatment, or receiving a non-trial treatment. When treatment is given over time 
(for example, a drug for HIV treatment), departures also occur over time, and often include 
starting a new treatment in response to a disease-related event.
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This paper specifically focuses on the case of treatment switching over time, where 
participants may switch to receive the other trial treatment during the trial (Latimer et al., 
2014). A common example is in a trial of active treatment versus placebo where placebo arm 
participants may start the active treatment in response to disease progression.
A randomised controlled trial with departures from randomised treatment is commonly 
analysed by intention-to-treat, in which departures from randomised treatment are ignored 
and all randomised participants are compared in the groups to which they were randomised 
(Higgins et al., 2011). This provides an unbiased comparison of two treatment policies, 
which accept that treatment may be changed, but does not compare the efficacies of the 
treatments themselves (White et al., 1999).
In order to compare the efficacies of the treatments, analysts often use per-protocol analysis, 
which censors participants when they depart from randomised treatment. However, this loses 
the advantage that randomisation produces comparable groups and instead introduces 
selection bias. Another possibility is to include treatment as a time-dependent variable in a 
Cox regression model. The issue with this method is that the estimate of treatment effect 
may not have a causal interpretation when switchers are prognostically different to non-
switchers (Robins and Tsiatis, 1991).
There has therefore been strong interest in causal inference methods including marginal 
structural models (MSM) (i.e. inverse probability of censoring weighting (IPCW)) (Hernán 
et al., 2001) and instrumental-variable-type methods (White, 2005; Watkins et al., 2013).
The IPCW method is an extension of the per-protocol censoring approach, whereby the bias 
associated with censoring participants that depart from randomised treatment is removed by 
weighting the remaining non-switchers (Latimer et al., 2016). A model is formed for the 
probability of switching using baseline and time-dependent covariates. Time-varying 
weights are then obtained for each participant based on the inverse probability of not 
switching until a given time (Watkins et al., 2013). The method relies on data on prognostic 
factors for mortality that also affect the probability of switching being collected at both 
baseline and over time. This is called the ‘no unmeasured confounders’ assumption. Since 
this assumption is untestable, the method relies on good planning at the study design stage in 
order to collect information on all possible confounders. The method also has two potential 
issues: a) if many prognostic factors are included in the model to calculate weights the 
model may fail to converge, and b) if only a few participants switch then large weights are 
assigned to the remaining participants, which may result in biased analyses. The method has 
already been implemented in R in the package ipw and so is not considered further here.
Instead, this paper focuses on a popular causal method - the rank preserving structural 
failure time model (RPSFTM) (Robins and Tsiatis, 1991). In contrast to the IPCW method 
which requires potential confounders to be collected over time, the RPSFTM is 
randomisation based and only requires information on the randomised treatment group, 
observed event times, and treatment history in order to estimate a causal treatment effect. 
The method has been used, for example, in submissions to the UK’s National Institute for 
Health and Clinical Excellence whose Decision Support Unit commissioned a guidance 
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document (Latimer and Abrams, 2014). The RPSFTM has been implemented in Stata 
(White et al., 2002) but not in R.
This paper describes the theory of the RPSFTM and presents a new implementation of the 
method in R, using data based on a trial in HIV infection.
Theory
RPSFTM method and assumptions
The RPSFTM uses a causal model to produce counter-factual event times (the time that 
would be observed if no treatment were received) in order to estimate a causal treatment 
effect. Let  be the observed event time for participant i, where  and 
represent the time spent off and on treatment, respectively. The Ti are related to the counter-
factual event times, Ui, via the following causal model:
(1)
where exp(-ψ0) is the acceleration factor associated with treatment and ψ0 is the true causal 
parameter.
A grid search (g-estimation) procedure is used to estimate the treatment effect that balances 
the counter-factual event times across randomised treatment groups. To estimate the causal 
treatment effect, ψ, we assume that the Ui are independent of randomised treatment group 
Ri, i.e. if the groups are similar with respect to all other characteristics except treatment, the 
average event times should be the same in each group if no participant were treated. In 
general, this assumption is plausible in a randomised controlled trial.
A g-estimation procedure is used to find the value of ψ such that Ui is independent of Ri. 
For a range of ψs, the hypothesis ψ0 = ψ is tested by computing Ui(ψ), subject to censoring, 
and calculating the test statistic Z(ψ). This is usually the same test statistic as for the 
intention-to-treat analysis, for example, the log rank test statistic to compare survival 
distributions between groups. In the rpsftm() function, the possible test options are the log 
rank, and the Wald test from a Cox or Weibull regression model. For the parametric Weibull 
test, the point estimate (ψ̂) is the value of ψ for which Z(ψ) = 0. For the non-parametric 
tests (log rank, Cox), ψ̂ is the value of ψ for which Z(ψ) crosses 0, since Z(ψ) is a step 
function. Confidence intervals are similarly found with the 100(1 − α)% confidence interval 
being the set {ψ : |Z(ψ)| < z1−α/2}, where z1−α/2 is the 1 − α/2 percentile of the standard 
normal distribution.
After finding ψ̂, an adjusted hazard ratio can be calculated. For example, by comparing 
counter-factual event times at ψ̂ in the control group to the observed event times in the 
experimental group we can estimate the treatment effect that would have been observed in 
the absence of switching (in the case where only the control group switch).
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As well as assuming that the only difference between randomised groups is the treatment 
received, the RPSFTM also assumes a ’common treatment effect’. The common treatment 
effect assumption states that the treatment effect is the same for all participants (with respect 
to time spent on treatment) regardless of when treatment is received, which is implicit in 
equation (1).
Re-censoring
We assume that censoring occurs if participants survive to a specific calendar date (Robins 
and Tsiatis, 1991). Thus the potential censoring time Ci is known for all participants. The 
censoring indicators of the observed event times are initially carried over to the counter-
factual event times. However, the uninformative censoring on the Ti scale may be 
informative on the Ui scale. Suppose we have two participants with the same Ui, one of 
whom receives the superior treatment. The participant receiving the superior treatment has 
their Ui extended so that they are censored whilst the other participant may observe the 
event.
In detail, Ci, the censoring times for the Ti, are transformed to Ci (1 − Pi + Pi exp(ψ)) when 
we work on the Ui scale, where Pi is a random variable, the proportion of time on treatment, 
 This transformation of censoring times occurs by representing the 
censoring status in two equivalent ways: {Ci < Ti}, and re-scaling both sides {Ci (1 − Pi + Pi 
exp(ψ)) < Ti (1 − Pi + Pi exp(ψ)) = Ui}. We cannot assume the variable Pi is independent of 
Ui. For example, adherence to a protocolised treatment may depend on the underlying 
prognosis.
We can overcome this induced dependence by considering the sample space for Pi 
marginally over Ui and, optionally, conditioning on Ri. If we replace Pi with a function of its 
sample space then any dependency on Ui is thus removed. Any alternative transformed 
censoring times must be smaller than the original censoring times, else we may have to 
impute uncensored Ui values for censored Ti observations, which would be impossible. 
Hence taking the minimum value from the sample space for Pi meets both desiderata. If the 
sample space differs between arms, say switching is impossible in one arm, then this can be 
utilised to potentially observe more events with gains in efficiency.
Operationally, let Ci be the potential censoring time for participant i. A participant is then 
recensored at the minimum possible censoring time:
If  then Ui is replaced by  and the censoring indicator is replaced by 0. For 
treatment arms where switching does not occur, there can be no informative censoring and 
so re-censoring is not applied.
Sensitivity analysis
As previously mentioned, the RPSFTM has two assumptions:
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1. The only difference between randomised groups is the treatment received.
2. The treatment effect is the same for all participants regardless of when treatment 
is received.
Whilst the first assumption is plausible in a randomised controlled trial, the latter may be 
unlikely to hold. For example, if control group participants can only switch at disease 
progression then the treatment benefit may be different in these participants compared to 
those randomised to the experimental treatment. The rpsftm() function allows for 
investigation of deviations from the common treatment effect assumption by featuring a 
treatment-effect modifier variable which means the treatment effect can be varied across 
participants. The assumption that defines the counter-factual treatment-free event times Ui is 
thus modified by multiplying ψ by some factor ki > 0:
The value taken by ki is derived from observed data and is left to the user to assign.
The package assumes that ki is determined at baseline, and re-censoring is undertaken in a 
similar way by re-censoring at the minimum possible censoring time:
Again, if  then Ui is replaced by  and the censoring indicator is replaced 
by 0. The case where ki is observed post randomisation is equally valid in terms of defining 
Ui, but more complicated re-censoring may be required, taking the minimum value of 
over the sample space of ki conditional on arm. This is not implemented in the package.
Using package rpsftm
The main function in the package rpsftm is of the same name, rpsftm(), which returns an 
object that has print, summary, and plot methods. The arguments to rpsftm() are given 
in table 1 below.
Example
The rpsftm function will be illustrated using a simulated dataset immdef taken from 
(White et al., 2002), based on a randomized controlled trial (Concorde Coordinating 
Committee, 1994). The trial compares two policies (immediate or deferred treatment) of 
zidovudine treatment in symptom free participants infected with HIV. The immediate 
treatment arm received treatment at randomisation whilst the deferred arm received 
treatment either at onset of AIDS related complex or AIDS (CDC group IV disease) or 
development of persistently low CD4 count. The endpoint considered here was time from 
study entry to progression to AIDS, or CDC group IV disease, or death.
Data
The immdef data frame has 1000 rows of 9 variables as described in table 2
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The first six observations are given below
 > library(rpsftm)
 > head(immdef)
   id def imm censyrs xo     xoyrs prog  progyrs entry
 1  1   0   1       3  0  0.000000    0 3.000000     0
 2  2   1   0       3  1  2.652797    0 3.000000     0
 3  3   0   1       3  0  0.000000    1 1.737838     0
 4  4   0   1       3  0  0.000000    1 2.166291     0
 5  5   1   0       3  1  2.122100    1 2.884646     0
 6  6   1   0       3  1  0.557392    0 3.000000     0
For example, participant 2 was randomised to the deferred arm, started treatment at 2.65 
years and was censored at 3 years (the end of the study). Subject 3 was randomised to the 
immediate treatment arm and progressed (observed the event) at 1.74 years. Subject 5 was 
randomised to the deferred treatment arm, started treatment at 2.12 years and progressed at 
2.88 years. The trial lasted 3 years with staggered entry over the first 1.5 years. The variable 
censyrs gives the time from entry to the end of the trial.
Intention-to-treat analysis
First, we estimate the effect of giving zidovudine ignoring any treatment changes during the 
trial. This is found by fitting an accelerated failure time model using the eha package:
> library(eha)
> itt_fit <- aftreg(Surv(progyrs, prog) ~ imm, data = immdef)
> itt_fit
Call:
aftreg(formula = Surv(progyrs, prog) ~ imm, data = immdef)
Covariate          W.mean          Coef   Time-Accn se(Coef) Wald p
imm                0.510        -0.147       0.863    0.077  0.056
Baseline parameters:    
log(scale)                      1.404                   0.062  0.000
log(shape)                      0.392                   0.052  0.000
Baseline life expectancy:            
 
Events                    312
Total time at risk        1932.5
Max. log. likelihood      -855.14
LR test statistic         3.69
Degrees of freedom        1
Overall p-value           0.0548817
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The intention-to-treat estimate is −0.147 which means that lifetime is used up exp(−0.147) = 
0.863 times as fast when on zidovudine as when off zidovudine (or zidovudine extends 
lifetime by a factor of exp(0.147) = 1.16).
Fitting the RPSFTM
We now show how to use rpsftm with the immdef data. First, a variable rx for the 
proportion of time spent on treatment must be created:
rx <- with(immdef, 1-xoyrs/progyrs)
This sets rx to 1 in the immediate treatment arm (since no participants could switch to the 
deferred arm, and xoyrs=0 in such participants), 0 in the deferred arm participants that did 
not receive treatment (as xoyrs=progyrs in such participants) and 1-xoyrs/progyrs in 
the deferred arm participants that did receive treatment. Using the default options, the fitted 
model is
rpsftm_fit_lr <- rpsftm(formula=Surv(progyrs, prog) ~ rand(imm, rx),
                        data=immdef,
                        censor_time=censyrs)
The above formula fits an RPSFTM where progyrs is the observed event time, prog is the 
indicator of disease progression, imm is the randomised treatment group indicator, rx is the 
proportion of time spent on treatment and censyrs is the censoring time. The log rank test 
is used in finding the point estimate of ψ̂. Re-censoring is performed since the 
censor_time parameter is specified; if not specified then re-censoring would not be 
performed. After finding ψ̂, rpsftm refits the model at ψ̂ and produces a survdiff object 
of the counter-factual event times to be used in plotting Kaplan-Meier curves. The list of 
objects that the function returns is given in table 3.
The point estimate and 95% confidence interval (CI) can be returned using rpsftm_fit_lr
$psi and rpsftm_fit_lr$CI which gives ψ̂ = –0.181(–0.350, 0.002), slightly larger than 
in the intention-to-treat analysis. This means that lifetime is used up exp(–0.181) = 0.834 
times as fast when on zidovudine as when off zidovudine, i.e. the time to progression to 
AIDS, or CDC group IV disease, or death is longer when on zidovudine (treatment is 
beneficial). However, the confidence interval contains zero, which suggests the treatment 
effect is non-significant. The function plot() produces Kaplan-Meier curves of the 
counter-factual event times in each group and can be used to check that the distributions are 
indeed the same at ψ̂ as shown in figure 1
We now provide examples of using the Cox regression model and the Weibull model in 
place of the log rank test. To use the Wald test from a Cox regression model, we specify 
test=coxph in the function parameters. Covariates can also be included in the estimation 
procedure by adding them to the right hand side of the formula. For example, baseline 
covariates that are included in the intention-to-treat analysis may also be incorporated into 
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the estimation procedure of the RPSFTM. In the following example we add entry time as a 
covariate and use summary() to find the value of ψ̂ and its 95% CI.
> rpsftm_fit_cph <- rpsftm(formula=Surv(progyrs, prog) ~ rand(imm, rx) + 
entry,
+                     data=immdef,
+                     censor_time=censyrs,
+                     test=coxph)
> summary(rpsftm_fit_cph)
   arm     rx.Min.  rx.1st Qu. rx.Median      rx.Mean rx.3rd Qu.   rx.Max.
1    0 0.0000000   0.0000000 0.0000000  0.1574062  0.2547779 0.9770941
2    1 1.0000000   1.0000000 1.0000000  1.0000000  1.0000000 1.0000000
   n= 1000, number of events= 286
         coef exp(coef) se(coef)      z Pr(>|z|)
entry  0.1235     1.1315      0.1487  0.831       0.406
       exp(coef) exp(-coef) lower .95 upper .95
entry      1.131     0.8838    0.8454     1.514
Concordance= 0.514  (se = 0.018)
Rsquare= 0.001    (max possible= 0.976)
psi: -0.1811697
exp(psi): 0.8342938
Confidence Interval, psi -0.3496874 0.003370267
Confidence Interval, exp(psi)  0.7049084 1.003376
For the Weibull model we specify test=survreg in the function parameters. :
> rpsftm_fit_wb <- rpsftm(formula=Surv(progyrs, prog) ~ rand(imm, rx) + 
entry,
+                     data=immdef,
+                     censor_time=censyrs,
+                     test=survreg)
> summary(rpsftm_fit_wb)
  arm    rx.Min. rx.1st Qu. rx.Median    rx.Mean rx.3rd Qu.    rx.Max.
1   0 0.0000000  0.0000000 0.0000000  0.1574062  0.2547779    0.9770941
2   1 1.0000000  1.0000000 1.0000000  1.0000000  1.0000000    1.0000000
Call:
rpsftm(formula = Surv(progyrs, prog) ~ rand(imm, rx) + entry,
    data = immdef, censor_time = censyrs, test = survreg)
              Value Std. Error        z         p
(Intercept)  1.3881    0.0857 16.197 5.34e-59
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entry        -0.0582    0.0906 -0.642 5.21e-01
Log(scale)  -0.4176    0.0568 -7.349 2.00e-13
Scale= 0.659
Weibull distribution
Loglik(model)= -759.8    Loglik(intercept only)= -760
Number of Newton-Raphson Iterations: 6
n= 1000
psi: -0.1811851
exp(psi): 0.8342809
Confidence Interval, psi -0.3501459 0.005170935
Confidence Interval, exp(psi)  0.7045852 1.005184
As we can see from the output for the Cox and Weibull models, the estimates of ψ are 
similar to the estimate obtained from using the log rank test. Both fitted models could be 
used as inputs to the plot() function, which produce figures very similar to figure 1.
As a sensitivity analysis we can investigate what would happen to the estimate of ψ if the 
treatment effect in the deferred treatment group was half of that in the immediate treatment 
group by setting ki = 1 for participants in the latter group and ki = 0.5 for participants in the 
former group.
> weight <- with(immdef, ifelse(imm==1, 1, 0.5))
> rpsftm(Surv(progyrs, prog) ~ rand(imm, rx), data = immdef, censor_time = 
censyrs,
+    treat_modifier = weight
+    )
 arm    rx.Min. rx.1st Qu. rx.Median   rx.Mean rx.3rd Qu.   rx.Max.
1  0  0.0000000  0.0000000 0.0000000 0.1574062  0.2547779 0.9770941
2  1  1.0000000  1.0000000 1.0000000 1.0000000  1.0000000 1.0000000
Call:
rpsftm(formula = Surv(progyrs, prog) ~ rand(imm, rx), data = immdef,
    censor_time = censyrs, treat_modifier = weight)
         N Observed Expected (O-E)^2/E (O-E)^2/V
.arm=0 500    157     157  5.75e-07  1.22e-06
.arm=1 500      143      143  6.31e-07  1.22e-06
Chisq= 0  on 1 degrees of freedom, p= 0.999
psi: -0.1704745
exp(psi): 0.8432646
Allison et al. Page 9
R J. Author manuscript; available in PMC 2018 March 19.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
In this case the estimate of treatment effect is reduced slightly to −0.170 and lifetime is used 
up 0.843 times as fast when on treatment as when off treatment.
Trouble Shooting
There is no guarantee that unique solutions exist to the estimating equations for the estimate 
and confidence interval limits, or that we have searched a wide enough interval to find them 
if they do exist and are unique.
There are three instances where rpsftm will produce warning messages due to the search 
interval. The function first evaluates Z(ψ) at low_psi and hi_psi and will produce a 
warning message if Z(ψ) is the same sign at these two points and no root exists within the 
interval.
Warning messages:
1: In rpsftm(formula = Surv(progyrs, prog) ~ rand(imm, rx), data = immdef,  :
The starting interval (-1, -0.9) to search for a solution for psi 
gives values of the same sign (7.53, 6.88).
Try a wider interval. plot(obj$eval_z, type="s"), where obj is the output of 
rpsftm() 
2: In rpsftm(formula = Surv(progyrs, prog) ~ rand(imm, rx), data = immdef,  :
  Evaluation of the estimated values of psi failed. It is set to NA
3: In rpsftm(formula = Surv(progyrs, prog) ~ rand(imm, rx), data = 
immdef,  : 
  Evaluation of a limit of the Confidence Interval failed.  It is set to NA
4: In rpsftm(formula = Surv(progyrs, prog) ~ rand(imm, rx), data = 
immdef,  : 
  Evaluation of a limit of the Confidence Interval failed.  It is set to NA
This suggests widening the search interval via trial and error until a root for ψ can be found 
between low_psi and hi_psi. The second warning message occurs when uniroot.all, 
the function used to solve the estimating equation for ψ̂ and its 95% confidence interval 
limits, fails to find any one of these. It will set the value to NA and produce the following 
warning message
> rpsftm_fit <- rpsftm(formula=Surv(progyrs, prog) ~ rand(imm, rx),
+                   data=immdef,
+                   censor_time=censyrs,
+                   low_psi=-1,
+                   hi_psi=-0.1)
Warning message:
In rpsftm(formula = Surv(progyrs, prog) ~ rand(imm, rx), data = immdef,  :
  Evaluation of a limit of the Confidence Interval failed.  It is set to NA
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Investigation of a plot of Z(ψ) against ψ in figure 2 for a range of values of ψ could show 
why the function fails to find a root. The fitted object, rpsftm_fit, returns a data frame 
rpsftm_fit$eval_z with values of the Z-statistic evaluated at 100 points between the 
limits of the search interval. The data frame can be supplied as the argument to plot() to 
visualise the estimating equation.
plot(rpsftm_fit$eval_z, type="s", ylim=c(-2, 6))
abline(h=qnorm(c(0.025, 0.5, 0.975)))
abline(v=rpsftm_fit$psi)
abline(v=rpsftm_fit$CI)
In this case, we see that the search interval used was not wide enough to find the upper 
confidence limit. The third warning message occurs when multiple roots are found:
Warning message:
In root(0) : Multiple Roots found
In order to show what happens when multiple roots are found, a subset of the immdef 
dataset was created and is stored within the test area of rpsftm. Whilst the function 
uniroot.all will return multiple roots, the function rpsftm will only display the first root 
found by uniroot.all. A plot of Z(ψ) against ψ can be used to find the other roots.
The limits of the confidence intervals may not exist at all if Z(·) reaches an asymptote before 
it hits the required quantile of the standard normal distribution, in which case the limits 
should be reported as ± ∞. This scenario would be illustrated by a similar plot to figure 2.
Another possibility is for the coxph function to fail to converge. This occurs when the 
maximum likelihood estimate of a coefficient is infinity, e.g. if one of the treatment groups 
has no events. The coxph documentation states that the Wald statistic should be ignored in 
this case and therefore the rpsftm output should be taken with caution.
Limitations
As well as the potential computational issues highlighted in the previous section, the 
RPSFTM itself has some limitations. The method relies on the assumption that the treatment 
effect is the same for all participants regardless of when treatment is received. We have 
allowed for investigation of deviations from this assumption within the rpsftm() function 
by adding a treatment-effect modifier variable. Another possible limitation of the model is 
its requirement for only the total amount of time spent on/off treatment. In instances where 
participants can switch back and forth between treatments the model may be inefficient.
Conclusion
The intention is to fill a void in the methodology available to R users by providing this 
package and thus facilitate the adoption of newer methods in application to real data in 
future. The sensitivity analyses, which generalise the definition of the counter-factual 
treatment-free event times, are an original development.
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Further developments to the package may include expanding the functionality to allow 
multi-armed studies with three or more arms. Such an extension would have at its core a set 
of g-estimating equations to solve, one for each element of the vector of ψ parameters. 
Defining the syntax to capture the multi-dimensional metric of time on treatments is 
challenging, as will be the numerical computational details when the g-estimating equations 
are step functions.
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Figure 1. 
Output from plot(rpsftm_fit_lr)
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Figure 2. 
Plot of Z(ψ) against ψ to detect problems with the choice of search interval
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Table 1
Arguments for the rpsftm() function
rpsftm() arguments
formula a formula with a minimal structure of Surv(time,status) ~rand(arm,rx) where
• arm is the randomised treatment arm
• rx is the proportion of time spent on treatment, taking values in [0, 1].
Further terms can be added to the right hand side to adjust for covariates.
data an optional data frame containing the variables
censor_time variable or constant giving the time at which censoring would, or has occurred. This should be provided for all 
observations unlike standard Kaplan-Meier or Cox regression where it is only given for censored observations. If no 
value is given then re-censoring is not applied.
subset an expression indicating which subset of the rows of data should be used in the fit. This can be a logical vector, a 
numeric vector indicating which observation numbers are to be included, or a character vector of row names to be 
included. All observations are included by default.
na.action a missing-data filter function. This is applied to the model.frame after any subset argument has been used. 
Default is options()$na.action.
test one of survdiff, coxph or survreg. Describes the test to be used in the estimating equation. Default 
is survdiff.
low_psi the lower limit of the range to search for the causal parameter. Default is −1.
hi_psi the upper limit of the range to search for the causal parameter. Default is 1.
alpha the significance level used to calculate the confidence intervals. Default is 0.05.
treat_modifier an optional variable that ψ is multiplied by on an participant observation level to give differing impact to treatment. 
Default is 1.
autoswitch a logical to autodetect cases of no switching. Default is TRUE. If all observations in an arm have perfect 
compliance then re-censoring is not applied in that arm. If FALSE then re-censoring is applied regardless of 
perfect compliance.
n_eval_z The number of points between hi_psi and low_psi at which to evaluate the Z-statistics in the estimating 
equation. Default is 100.
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Table 2
Description of simulated data set
immdef variables
id participant ID number
def indicator that the participant was assigned to the Deferred treatment arm
imm indicator that the participant was assigned to the Immediate treatment arm
censyrs censoring time, in years, corresponding to the close of study minus the time of entry for each participant
xo an indicator that switching occurred
xoyrs the time, in years, from entry to switching, or 0 for participants in the Immediate arm
prog an indicator of disease progression (1), or censoring (0)
progyrs time, in years, from entry to disease progression or censoring
entry the time of entry into the study, measured in years from the date of randomisation
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Table 3
Outputs from the rpsftm() function
rpsftm() outputs
psi the estimated parameter
fit a survdiff object to produce Kaplan-Meier curves of the estimated counter-factual event times in each treatment arm using 
plot()
CI a vector of the confidence interval around psi
Sstar the (possibly) re-censored Surv() data using the estimate value of psi to give counterfactual untreated failure times.
rand the rand() object used to specify the allocated and observed amount of treatment.
ans the values from uniroot.all used to solve the estimating equation, but embedded within a list as per uniroot, with 
an extra element root_all, a vector of all roots found in the case of multiple solutions. The first element of root_all 
is subsequently used.
eval_z a data frame with the Z-statistics from the estimating equation evaluated at a sequence of values of psi. Used to plot and check 
if the range of values to search for solution and limits of confidence intervals need to be modified.
Further elements corresponding to either a survdiff, coxph, or survreg object. This will always include:
call the R call object
formula a formula representing any adjustments, strata or clusters - used for the update() function
terms a more detailed representation of the model formula
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